Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Logopenic progressive aphasia


Other Names for this Disease
  • LPA
  • Logopenic primary progressive aphasia
  • Logopenic variant PPA
Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

Two questions if I may: Is there any know medications or treatment that can be used for this condition? What can the life expectancy be? 

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

What is the typical life expectancy for people with logopenic progressive aphasia?

Little is known regarding the overall life expectancy of individuals with logopenic progressive aphasia. This dementia is associated with Alzheimer’s disease in the majority of cases.[1] Life expectancy for people with Alzheimer’s disease has been estimated to be between 3 to 10 years.[2] However, due to the many variables that influence life expectancy, making individualized life-expectancy predictions can be very difficult.
Last updated: 1/18/2013

How might logopenic progressive aphasia be treated?

Although no medications or interventions have demonstrated long-term stabilization of logopenic progressive aphasia (LPA), different treatment methods have shown promising short-term benefits.[3][4] Studies utilizing language therapy and behavioral interventions have shown encouraging results. Neuromodulation through methodologies such as Transcranial Direct Current Stimulation (tDCS) and transcranial magnetic stimulation (rTMS) have additionally been identified as a promising therapies to potentially use in combination with behavioral treatment and language therapy.[3]

As the most common underlying pathology of LPA is Alzheimer's disease (AD) pathology, limited research has been completed on interventions shown to reduce the rate of decline in cognitive symptoms in AD. So far cholinesterase inhibitors and memantine, medications used in Alzheimer’s disease, have not been proven effective in treating logopenic progressive aphasia. Case studies involving steriod use and Omentum Transposition Therapy have reported improvement; however, the results have not been replicated in other cases and as with other treatment options, long-term studies are lacking.[3]

The National Aphasia Association provides further information on the medical management of primary progressive aphasias at the following link:

http://live-naa.pantheon.io/wp-content/uploads/2014/12/Managing-PPA.pdf
Last updated: 4/4/2016

References
  • Hsieh S, Hodges JR, Leyton CE, Mioshi E. Longitudinal changes in primary progressive aphasias: differences in cognitive and dementia staging measures. Dement Geriatr Cogn Disord. 2012;34(2):135-41; http://www.ncbi.nlm.nih.gov/pubmed/23006977. Accessed 1/18/2013.
  • Zanetti O, Solerte SB, Cantoni F. Life expectancy in Alzheimer's disease (AD). Arch Gerontol Geriatr. 2009;49 Suppl 1:237-43; http://www.ncbi.nlm.nih.gov/pubmed/19836639. Accessed 1/18/2013.
  • Donna C. Tippett, Argye E. Hillis,Kyrana Tsapkini. Treatment of Primary Progressive Aphasia. Curr Treat Options Neurol.. August 2015; 17(8):362. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600091/.
  • Beeson PM, King RM, Bonakdarpour B, Henry ML, Cho H, Rapcsak SZ. Positive effects of language treatment for the logopenic variant of primary progressive aphasia. J Mol Neurosci. 2011 Nov;45(3):724-36; http://www.ncbi.nlm.nih.gov/pubmed/21710364.
  • Miller BL Lee SE,. Frontotemporal dementia: Treatment. In: DeKosky ST, Eichler AF. UpToDate. Waltham, MA: UpToDate; 2013;
  • Le Rhun E, Richard F, Pasquier F. Natural history of primary progressive aphasia. Neurology. 2005 Sep 27;65(6):887-91; http://www.ncbi.nlm.nih.gov/pubmed/16186529. Accessed 1/18/2013.
  • Amici S, Gorno-Tempini ML, Ogar JM, Dronkers NF, Miller BL. An overview on Primary Progressive Aphasia and its variants. Behav Neurol. 2006;17(2):77-87; http://www.ncbi.nlm.nih.gov/pubmed/16873918. Accessed 1/18/2013.
  • Randolph C . Frontotermporal dementia: Clinical features and diganosis. In: DeKasky ST, Eichler AF. UpToDate. Waltham, MA: UpToDate; 2012;
Other Names for this Disease
  • LPA
  • Logopenic primary progressive aphasia
  • Logopenic variant PPA
Related Diseases
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.